首页> 外文期刊>Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association >Immunohistochemical Analysis of VEGF-C/VEGFR-3 System and Lymphatic Vessel Extent in Normal and Adenomatous Human Pituitary Tissues.
【24h】

Immunohistochemical Analysis of VEGF-C/VEGFR-3 System and Lymphatic Vessel Extent in Normal and Adenomatous Human Pituitary Tissues.

机译:正常和腺瘤性人垂体组织中VEGF-C / VEGFR-3系统和淋巴管范围的免疫组织化学分析。

获取原文
获取原文并翻译 | 示例
           

摘要

The angiogenic growth factor Vascular Endothelial Growth Factor-C (VEGF-C) and its receptor VEGFR-3 are also known to be implicated in the development of lymphatic vessels. We assessed the expression of VEGF-C and VEGFR-3, together with blood and lymphatic vessel extents and proliferation index (PI) values, by immunohistochemistry (IHC) in 6 normal human pituitary glands and 53 pituitary adenomas of different tumour grade, on consecutive tissue sections. VEGF-C was detected in around 10% of the endocrine cells in normal pituitary tissue, while this gland was devoid of lymphatic vascularization and showed very few vessels positive for VEGFR-3. Concerning tumour tissue, most of the adenomas showing VEGF-C immunoreactivity (21/47) were positive in 60% of the tumour cells and the ones positive for VEGFR-3 showed a number of immunostained vessels higher than those observed in the normal pituitary. Most of the tumours positive for VEGFR-3 did not show any LYVE-1 positive vessels (18/53), suggesting that at least in these cases, VEGFR-3 is expressed on blood vessels. Nevertheless, we observed a significant association between low expression of VEGFR-3 and low lymphatic vessel number, suggesting that VEGFR-3 might be involved in the starting of DE NOVO lymphangiogenesis in this tumour type. Moreover, tumours bearing lymphatic vessels showed the tendency to shift towards a more aggressive behaviour (high tumour grade and high PI). In conclusion, the VEGF-C/VEGFR-3 system might be involved in controlling tumour angiogenesis in the pituitary adenomas lacking lymphatic vessels, but may also play a role in starting the process of tumour lymphangiogenesis.
机译:还已知血管生成生长因子血管内皮生长因子-C(VEGF-C)及其受体VEGFR-3与淋巴管的发育有关。我们通过免疫组织化学(IHC)评估了6个正常人垂体和53个不同肿瘤等级的垂体腺瘤中VEGF-C和VEGFR-3的表达,以及血液和淋巴管的程度以及增殖指数(PI)值,连续进行组织切片。在正常垂体组织的大约10%的内分泌细胞中检测到VEGF-C,而该腺体无淋巴管血管化,显示出极少的VEGFR-3阳性血管。关于肿瘤组织,大多数显示VEGF-C免疫反应性的腺瘤(21/47)在60%的肿瘤细胞中是阳性的,而VEGFR-3阳性的腺瘤则显示出比正常垂体中观察到的更高的免疫染色的血管。对VEGFR-3呈阳性的大多数肿瘤未显示任何LYVE-1阳性血管(18/53),这表明至少在这些情况下,VEGFR-3在血管上表达。然而,我们观察到VEGFR-3的低表达与低的淋巴管数目之间存在显着的关联,这表明VEGFR-3可能参与了该类型肿瘤的DE NOVO淋巴管生成。此外,带有淋巴管的肿瘤表现出趋向于更具攻击性的行为(高肿瘤等级和高PI)的趋势。总之,VEGF-C / VEGFR-3系统可能参与控制缺乏淋巴管的垂体腺瘤中的肿瘤血管生成,但也可能在启动肿瘤淋巴血管生成过程中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号